PL-52

PL-52 is a preclinical-stage proteolysis-targeting chimera (PROTAC) small molecule being developed by Jiangsu ProteLight Pharmaceutical & Biotechnology. It is currently under investigation for the treatment of solid tumors, specifically triple-negative breast cancer (TNBC) and colorectal cancer (CRC). As a PROTAC, PL-52 is designed to induce the targeted degradation of a specific protein—the identity of which has not yet been disclosed by the developer—by recruiting an E3 ubiquitin ligase to the target, leading to its ubiquitination and subsequent degradation via the 26S proteasome. This approach aims to provide a therapeutic advantage over traditional small-molecule inhibitors by completely removing the disease-causing protein from the cell.